Gain Therapeutics Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
25
- Stock Symbol
-
GANX
- Share Price
-
$1.00
- (As of Friday Closing)
Gain Therapeutics General Information
Description
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
Contact Information
Website
www.gaintherapeutics.comCorporate Office
- 4800 Montgomery Lane
- Suite 220
- Bethesda, MD 20814
- United States
Corporate Office
- 4800 Montgomery Lane
- Suite 220
- Bethesda, MD 20814
- United States
Gain Therapeutics Stock Performance
As of 20-Nov-2026, Gain Therapeutics’s stock price is $1.00. Its current market cap is $44.5M with 44.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.00 | $1.05 | $0.94 - $4.34 | $44.5M | 44.5M | 547K | -$0.42 |
Gain Therapeutics Financials Summary
As of 30-Sep-2026, Gain Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 63,029 | 115,646 | 46,014 | 41,697 |
| Revenue | 0 | 0 | 0 | 55 |
| EBITDA | (17,736) | (19,450) | (20,146) | (22,599) |
| Net Income | (17,982) | (20,161) | (20,411) | (22,268) |
| Total Assets | 13,232 | 22,819 | 12,124 | 18,609 |
| Total Debt | 677 | 732 | 653 | 1,027 |
Gain Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Gain Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Gain Therapeutics Comparisons
Industry
Financing
Details
Gain Therapeutics Competitors (12)
One of Gain Therapeutics’s 12 competitors is Polaryx Therapeutics, a Formerly VC-backed company based in NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Polaryx Therapeutics | Formerly VC-backed | NJ | ||||
| Prevail Therapeutics | Formerly VC-backed | New York, NY | ||||
| Capsida Biotherapeutics | Venture Capital-Backed | Thousand Oaks, CA | ||||
| Aspen Neuroscience | Formerly VC-backed | San Diego, CA | ||||
| Neurometa Therapeutics | Accelerator/Incubator Backed | Aalborg, Denmark |
Gain Therapeutics Patents
Gain Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026190683-A1 | Combination therapy comprising heteroaryl compound for treatment of cancer | Pending | 11-Mar-2025 | ||
| WO-2025215582-A1 | Substituted pyrazolopyridine and pyrazolopyrimidine compounds and their use | Pending | 11-Apr-2024 | ||
| AU-2024371889-A1 | Substituted indolyl compounds, compositions thereof, and therapeutic uses thereof | Pending | 02-Nov-2023 | ||
| EP-4801902-A1 | Substituted indolyl compounds, compositions thereof, and therapeutic uses thereof | Pending | 02-Nov-2023 | ||
| WO-2025094117-A1 | Substituted indolyl compounds, compositions thereof, and therapeutic uses thereof | Inactive | 02-Nov-2023 | C07D401/04 |
Gain Therapeutics Signals
Gain Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
39.09 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Gain Therapeutics FAQs
-
When was Gain Therapeutics founded?
Gain Therapeutics was founded in 2017.
-
Where is Gain Therapeutics headquartered?
Gain Therapeutics is headquartered in Bethesda, MD.
-
What is the size of Gain Therapeutics?
Gain Therapeutics has 25 total employees.
-
What industry is Gain Therapeutics in?
Gain Therapeutics’s primary industry is Drug Discovery.
-
Is Gain Therapeutics a private or public company?
Gain Therapeutics is a Public company.
-
What is Gain Therapeutics’s stock symbol?
The ticker symbol for Gain Therapeutics is GANX.
-
What is the current stock price of Gain Therapeutics?
As of 20-Nov-2026 the stock price of Gain Therapeutics is $1.00.
-
What is the current market cap of Gain Therapeutics?
The current market capitalization of Gain Therapeutics is $44.5M.
-
Who are Gain Therapeutics’s competitors?
Polaryx Therapeutics, Prevail Therapeutics, Capsida Biotherapeutics, Aspen Neuroscience, and Neurometa Therapeutics are some of the 12 competitors of Gain Therapeutics.
-
What is Gain Therapeutics’s annual earnings per share (EPS)?
Gain Therapeutics’s EPS for 12 months was -$0.42.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process